117 related articles for article (PubMed ID: 24985169)
1. [Clinical analysis of 82 cases of primary mediastinal large B cell lymphoma].
Wang J; Hu C; Zhao Y; Yi P; Huang M; Zhang G
Zhonghua Xue Ye Xue Za Zhi; 2014 Jun; 35(6):491-4. PubMed ID: 24985169
[TBL] [Abstract][Full Text] [Related]
2. [Primary mediastinal large B-cell lymphoma:a report of 24 cases with literature review].
Chen DG; Yang Y; Pan CZ
Ai Zheng; 2008 Feb; 27(2):187-90. PubMed ID: 18279619
[TBL] [Abstract][Full Text] [Related]
3. Isolated central nervous system relapses in primary mediastinal large B-cell lymphoma after CHOP-like chemotherapy with or without Rituximab.
Papageorgiou SG; Diamantopoulos P; Levidou G; Angelopoulou MK; Economopoulou P; Efthimiou A; Constantinou N; Katsigiannis A; Korkolopoulou P; Pappa V; Economopoulou C; Georgiou G; Dimou M; Tsirigotis P; Kyrtsonis MC; Kotsianidis I; Kalpadakis C; Dimopoulos MA; Beris P; Meletis J; Pangalis GA; Dervenoulas J; Panayiotidis P; Vassilakopoulos TP
Hematol Oncol; 2013 Mar; 31(1):10-7. PubMed ID: 22610484
[TBL] [Abstract][Full Text] [Related]
4. CHOP-like chemotherapy with or without rituximab in young patients with good-prognosis diffuse large-B-cell lymphoma: 6-year results of an open-label randomised study of the MabThera International Trial (MInT) Group.
Pfreundschuh M; Kuhnt E; Trümper L; Osterborg A; Trneny M; Shepherd L; Gill DS; Walewski J; Pettengell R; Jaeger U; Zinzani PL; Shpilberg O; Kvaloy S; de Nully Brown P; Stahel R; Milpied N; López-Guillermo A; Poeschel V; Grass S; Loeffler M; Murawski N;
Lancet Oncol; 2011 Oct; 12(11):1013-22. PubMed ID: 21940214
[TBL] [Abstract][Full Text] [Related]
5. Primary mediastinal large B-cell lymphoma (PMLBCL): long-term results from a retrospective multicentre Italian experience in 138 patients treated with CHOP or MACOP-B/VACOP-B.
Todeschini G; Secchi S; Morra E; Vitolo U; Orlandi E; Pasini F; Gallo E; Ambrosetti A; Tecchio C; Tarella C; Gabbas A; Gallamini A; Gargantini L; Pizzuti M; Fioritoni G; Gottin L; Rossi G; Lazzarino M; Menestrina F; Paulli M; Palestro M; Cabras MG; Di Vito F; Pizzolo G
Br J Cancer; 2004 Jan; 90(2):372-6. PubMed ID: 14735179
[TBL] [Abstract][Full Text] [Related]
6. [Clinical characteristics and outcomes of 31 patients with primary bone lymphoma].
Zhu Y; Yue C; Wu B; Ping B
Nan Fang Yi Ke Da Xue Xue Bao; 2013 Mar; 33(3):444-7. PubMed ID: 23529250
[TBL] [Abstract][Full Text] [Related]
7. Prognostic significance of maximum tumour (bulk) diameter in young patients with good-prognosis diffuse large-B-cell lymphoma treated with CHOP-like chemotherapy with or without rituximab: an exploratory analysis of the MabThera International Trial Group (MInT) study.
Pfreundschuh M; Ho AD; Cavallin-Stahl E; Wolf M; Pettengell R; Vasova I; Belch A; Walewski J; Zinzani PL; Mingrone W; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Corrado C; Scheliga A; Loeffler M; Kuhnt E;
Lancet Oncol; 2008 May; 9(5):435-44. PubMed ID: 18400558
[TBL] [Abstract][Full Text] [Related]
8. Primary mediastinal large B-cell lymphoma (PMLBCL) in Chinese patients: clinical characteristics and prognostic factors.
Zhu YJ; Huang JJ; Xia Y; Zhao W; Jiang WQ; Lin TY; Huang HQ; Li ZM
Int J Hematol; 2011 Aug; 94(2):178-184. PubMed ID: 21800075
[TBL] [Abstract][Full Text] [Related]
9. Comparison of prognostic models for patients with diffuse large B-cell lymphoma in the rituximab era.
Huang YC; Liu CY; Lu HJ; Liu HT; Hung MH; Hong YC; Hsiao LT; Gau JP; Liu JH; Hsu HC; Chiou TJ; Chen PM; Tzeng CH; Yu YB
Ann Hematol; 2013 Nov; 92(11):1513-20. PubMed ID: 23775580
[TBL] [Abstract][Full Text] [Related]
10. High Ki67 index and bulky disease remain significant adverse prognostic factors in patients with diffuse large B cell lymphoma before and after the introduction of rituximab.
Gaudio F; Giordano A; Perrone T; Pastore D; Curci P; Delia M; Napoli A; de' Risi C; Spina A; Ricco R; Liso V; Specchia G
Acta Haematol; 2011; 126(1):44-51. PubMed ID: 21430371
[TBL] [Abstract][Full Text] [Related]
11. CHOP-like chemotherapy plus rituximab versus CHOP-like chemotherapy alone in young patients with good-prognosis diffuse large-B-cell lymphoma: a randomised controlled trial by the MabThera International Trial (MInT) Group.
Pfreundschuh M; Trümper L; Osterborg A; Pettengell R; Trneny M; Imrie K; Ma D; Gill D; Walewski J; Zinzani PL; Stahel R; Kvaloy S; Shpilberg O; Jaeger U; Hansen M; Lehtinen T; López-Guillermo A; Corrado C; Scheliga A; Milpied N; Mendila M; Rashford M; Kuhnt E; Loeffler M;
Lancet Oncol; 2006 May; 7(5):379-91. PubMed ID: 16648042
[TBL] [Abstract][Full Text] [Related]
12. [Efficacy of rituximab-containing salvage regimens on relapsed or refractory B-cell non-Hodgkin's lymphoma].
Huang HQ; Bu Q; Xia ZJ; Lin XB; Wang FH; Li YH; Peng YL; Pan ZH; Wang SS; Lin TY; Jiang WQ; Guan ZZ
Ai Zheng; 2006 Apr; 25(4):486-9. PubMed ID: 16613686
[TBL] [Abstract][Full Text] [Related]
13. [Eight-year experience in treating aggressive mediastinal large B-cell lymphomas].
Mangasarova IaK; Magomedova AU; Kravchenko SK; Shmakov RG; Bariakh EA; Vorob'ev VI; Mar'in DS; Skidan NI; Gemdzhian ÉG; Misiurin AV; Kremenetskaia AM; Vorob'ev AI
Ter Arkh; 2013; 85(7):50-6. PubMed ID: 24137947
[TBL] [Abstract][Full Text] [Related]
14. A retrospective analysis of primary gastric diffuse large B-cell lymphoma with or without concomitant mucosa-associated lymphoid tissue (MALT) lymphoma components.
Li X; Xia B; Guo S; Zhan Z; Zhang L; Zhao D; Wu X; Zhang Y
Ann Hematol; 2013 Jun; 92(6):807-15. PubMed ID: 23417758
[TBL] [Abstract][Full Text] [Related]
15. [Clinical characteristics and long-term follow-up of 29 patients with primary mediastinal large B cell lymphoma].
Wang BJ; Cen XN; Qiu ZX; Ou JP; Wang WS; Liang ZY; Dong YJ; Xu WL; Li Y; Wang MJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Wang Y; Ren HY
Zhongguo Shi Yan Xue Ye Xue Za Zhi; 2014 Dec; 22(6):1596-602. PubMed ID: 25543481
[TBL] [Abstract][Full Text] [Related]
16. [Prognostic analysis of 525 Chinese patients with diffuse large B cell lymphoma].
Fu ZY; Zhu J; Song YQ; Liu WP; Ji XQ; Zhan SY
Beijing Da Xue Xue Bao Yi Xue Ban; 2014 Jun; 46(3):405-11. PubMed ID: 24943019
[TBL] [Abstract][Full Text] [Related]
17. [Combination of rituximab with autologous peripheral blood stem cell transplantation for treatment of diffuse large B-cell lymphoma: a single-center experience].
Liang ZY; Cen XN; Qiu ZX; Ou JP; Wang WS; Xu WL; Li Y; Wang MJ; Dong YJ; Wang LH; Yin Y; Sun YH; Liu W; Wang Q; Ren HY
Zhonghua Xue Ye Xue Za Zhi; 2012 Dec; 33(12):1033-7. PubMed ID: 23363798
[TBL] [Abstract][Full Text] [Related]
18. Rituximab in combination with CHOP chemotherapy for the treatment of diffuse large B cell lymphoma in China: a 10-year retrospective follow-up analysis of 437 cases from Shanghai Lymphoma Research Group.
Li X; Liu Z; Cao J; Hong X; Wang J; Chen F; Wang C; Zou S; Li J; Shen Z
Ann Hematol; 2012 Jun; 91(6):837-45. PubMed ID: 22160255
[TBL] [Abstract][Full Text] [Related]
19. The lymphocyte to monocyte ratio improves the IPI-risk definition of diffuse large B-cell lymphoma when rituximab is added to chemotherapy.
Rambaldi A; Boschini C; Gritti G; Delaini F; Oldani E; Rossi A; Barbui AM; Caracciolo D; Ladetto M; Gueli A; De Crescenzo A; Passera R; Devizzi L; Patti C; Gianni AM; Tarella C
Am J Hematol; 2013 Dec; 88(12):1062-7. PubMed ID: 23940056
[TBL] [Abstract][Full Text] [Related]
20. [Analysis of prognostic risk factors in patients with diffuse large B-cell lymphoma].
Yu ZP; Ding JH; Chen BA; Gao C; Wang LL; Chen Z
Zhonghua Xue Ye Xue Za Zhi; 2011 Dec; 32(12):830-5. PubMed ID: 22339956
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
